NVO Quote, Financials, Valuation and Earnings

Ascendis Pharma AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of -171.53%. Novo Nordisk AS's return on equity of 88.95% beat Ascendis Pharma AS's return on equity of -880.05%.

Novo Nordisk AS has a consensus price target of $115.40, signalling upside risk potential of 33.79%. On the other hand Ascendis Pharma AS has an analysts' consensus of $191.30 which suggests that it could grow by 48.08%. Given that Ascendis Pharma AS has higher upside potential than Novo Nordisk AS, analysts believe Ascendis Pharma AS is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.447, which suggesting that the stock is 55.342% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.145%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.68%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Ascendis Pharma AS quarterly revenues of $63.6M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$109.1M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.95x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.79x versus 20.78x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of -64.14%. Novo Nordisk AS's return on equity of 88.95% beat Evaxion Biotech AS's return on equity of --.

Novo Nordisk AS has a consensus price target of $115.40, signalling upside risk potential of 33.79%. On the other hand Evaxion Biotech AS has an analysts' consensus of $9.42 which suggests that it could grow by 1184.72%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.447, which suggesting that the stock is 55.342% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.68%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Novo Nordisk AS's net income of $4B is higher than Evaxion Biotech AS's net income of -$1.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.95x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.79x versus 1.25x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

TC BioPharm (Holdings) PLC has a net margin of 38.28% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 88.95% beat TC BioPharm (Holdings) PLC's return on equity of --.

Novo Nordisk AS has a consensus price target of $115.40, signalling upside risk potential of 33.79%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 499.25%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Novo Nordisk AS, analysts believe TC BioPharm (Holdings) PLC is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.447, which suggesting that the stock is 55.342% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.68%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.95x while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.79x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 38.28% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 88.95% beat Viking Therapeutics's return on equity of --.

Novo Nordisk AS has a consensus price target of $115.40, signalling upside risk potential of 33.79%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 179.83%. Given that Viking Therapeutics has higher upside potential than Novo Nordisk AS, analysts believe Viking Therapeutics is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.447, which suggesting that the stock is 55.342% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.68%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Viking Therapeutics quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Viking Therapeutics's net income of -$24.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.95x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.79x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.